Statin Use and the Risk of Cholecystectomy in Women

Gastroenterology

Volumn 136, Issue 5, 2009, Pages 1593-1600

  Tsai, Chung Jyi ^a,b   Leitzmann, Michael F ^d   Willett, Walter C ^b,c   Giovannucci, Edward L ^b,c  

^a UNIVERSITY OF KENTUCKY MEDICAL CENTER   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT;

ARTICLE; CHOLECYSTECTOMY; CHOLELITHIASIS; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RISK FACTOR;

EID: 65349098719     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.gastro.2009.01.042     Document Type: Article

References (55)

1. Beckingham I.J. ABC of diseases of liver, pancreas, and biliary system. Gallstone disease. BMJ 322 (2001) 91-94
2. National Center for Health Statistics: 2000. National hospital discharge survey. Advance Data from Vital and Health Statistics, Hyattsville, MD.
3. Kang J.Y., Ellis C., Majeed A., et al. Gallstones-an increasing problem: a study of hospital admissions in England between 1989/1990 and 1999/2000. Aliment Pharmacol Ther 17 (2003) 561-569
4. Dowling R.H. Pathogenesis of gallstones. Aliment Pharmacol Ther 14 Suppl 2 (2000) 39-47
5. Donovan J.M., and Konikoff F.M. Gallstone disease: pathogenesis and treatment. In: Schiff E.R., Sorrell M.F., and Maddrey W.C. (Eds). Schiff's diseases of the liver. 10th ed. (2007), Lippincott Williams & Wilkins, Philadelphia 639-663
6. Tazuma S., Yamashita G., Ochi H., et al. Effects of cerivastatin sodium, a new HMG-CoA reductase inhibitor, on biliary lipid metabolism in patients with hypercholesterolemia. Clin Ther 20 (1998) 477-485
7. Tazuma S., Kajiyama G., Mizuno T., et al. A combination therapy with simvastatin and ursodeoxycholic acid is more effective for cholesterol gallstone dissolution than is ursodeoxycholic acid monotherapy. J Clin Gastroenterol 26 (1998) 287-291
8. Tazuma S., Takizawa I., Kunita T., et al. Effects of long-term treatment with low-dose pravastatin on biliary lipid and bile acid composition in patients with nonfamilial hyperlipoproteinemia. Metabolism 44 (1995) 1410-1412
9. Hawk E., and Viner J.L. Statins and cancer-beyond the "one drug, one disease" model. N Engl J Med 352 (2005) 2238-2239
10. Poynter J.N., Gruber S.B., Higgins P.D., et al. Statins and the risk of colorectal cancer. N Engl J Med 352 (2005) 2184-2192
11. Hoffmann P., Roumeguere T., Schulman C., et al. Use of statins and outcome of BCG treatment for bladder cancer. N Engl J Med 355 (2006) 2705-2707
12. Lubitz S.A., Pinney S., Wisnivesky J.P., et al. Statin therapy associated with a reduced risk of chronic renal failure after cardiac transplantation. J Heart Lung Transplant 26 (2007) 264-272
13. Kallien G., Lange K., Stange E.F., et al. The pravastatin-induced decrease of biliary cholesterol secretion is not directly related to an inhibition of cholesterol synthesis in humans. Hepatology 30 (1999) 14-20
14. Nicholls S.J., Tuzcu E.M., Sipahi I., et al. Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis. JAMA 297 (2007) 499-508
15. Rogers S.L., Magliano D.J., Levison D.B., et al. A dose-specific meta-analysis of lipid changes in randomized controlled trials of atorvastatin and simvastatin. Clin Ther 29 (2007) 242-252
16. Mitchell J.C., Logan G.M., Stone B.G., et al. Effects of lovastatin on biliary lipid secretion and bile acid metabolism in humans. J Lipid Res 32 (1991) 71-78
17. Duane W.C., Hunninghake D.B., Freeman M.L., et al. Simvastatin, a competitive inhibitor of HMG-CoA reductase, lowers cholesterol saturation index of gallbladder bile. Hepatology 8 (1988) 1147-1150
18. Hoogerbrugge-vd Linden N., de Rooy F.W., Jansen H., et al. Effect of pravastatin on biliary lipid composition and bile acid synthesis in familial hypercholesterolaemia. Gut 31 (1990) 348-350
19. Porsch-Ozcurumez M., Hardt P.D., Schnell-Kretschmer H., et al. Effects of fluvastatin on biliary lipids in subjects with an elevated cholesterol saturation index. Eur J Clin Pharmacol 56 (2001) 873-879
20. Saunders K.D., Cates J.A., Abedin M.Z., et al. Lovastatin inhibits gallstone formation in the cholesterol-fed prairie dog. Ann Surg 214 (1991) 149-154
21. Tazuma S., Hatsushika S., Aihara N., et al. Inhibitory effects of pravastatin, a competitive inhibitor of hydroxymethylglutaryl coenzyme A reductase, on cholesterol gallstone formation in prairie dogs. Digestion 51 (1992) 179-184
22. Abedin M.Z., Narins S.C., Park E.H., et al. Lovastatin alters biliary lipid composition and dissolves gallstones: a long-term study in prairie dogs. Dig Dis Sci 47 (2002) 2192-2210
23. Smit J.W., van Erpecum K.J., Renooij W., et al. The effects of the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor pravastatin on bile composition and nucleation of cholesterol crystals in cholesterol gallstone disease. Hepatology 21 (1995) 1523-1529
24. Smit J.W., van Erpecum K.J., Stolk M.F., et al. Successful dissolution of cholesterol gallstone during treatment with pravastatin. Gastroenterology 103 (1992) 1068-1070
25. Smith J.L., Roach P.D., Wittenberg L.N., et al. Effects of simvastatin on hepatic cholesterol metabolism, bile lithogenicity and bile acid hydrophobicity in patients with gallstones. J Gastroenterol Hepatol 15 (2000) 871-879
26. Colditz G.A., Manson D.M., and Hankinson S.E. The Nurses' Health Study: 20-year contribution to the understanding of health among women. J Women's Health 6 (1997) 49-62
27. Lemaitre R.N., Furberg C.D., Newman A.B., et al. Time trends in the use of cholesterol-lowering agents in older adults: the Cardiovascular Health Study. Arch Intern Med 158 (1998) 1761-1768
28. Siegel D., Lopez J., and Meier J. Use of cholesterol-lowering medications in the United States from 1991 to 1997. Am J Med 108 (2000) 496-499
29. Willett W.C. Nutritional epidemiology. 2nd ed. (1998), Oxford University Press, New York
30. US Department of Agriculture. Composition of foods-raw, processed, and prepared, 1963-1992. Agricultural handbook no. 8 series (1993), Department of Agriculture, US Government Printing Office, Washington, DC
31. Leitzmann M.F., Rimm E.B., Willett W.C., et al. Recreational physical activity and the risk of cholecystectomy in women. N Engl J Med 341 (1999) 777-784
32. Maclure K.M., Hayes K.C., Colditz G.A., et al. Weight, diet, and the risk of symptomatic gallstones in middle-aged women. N Engl J Med 321 (1989) 563-569
33. Sleisenger M.H., and Fordtran J.S. Gastrointestinal and liver disease: pathophysiology, diagnosis, management (2002), WB Saunders, Philadelphia
34. Rothman K.J., Greenland S., and Lash T.L. Modern epidemiology (2008), Lippincott Williams & Wilkins, Philadelphia
35. Cox D.R., and Oakes D. Analysis of survival data (1984), Chapman & Hall, London
36. Flanders W.D., and Khoury M.J. Indirect assessment of confounding: graphic description and limits on effect of adjusting for covariates. Epidemiology 1 (1990) 239-246
37. Smit J.W., Van Erpecum K.J., Portincasa P., et al. Effects of simvastatin and cholestyramine on bile lipid composition and gall bladder motility in patients with hypercholesterolaemia. Gut 37 (1995) 654-659
38. Sharma B.C., Agarwal D.K., Baijal S.S., et al. Pravastatin has no effect on bile lipid composition, nucleation time, and gallbladder motility in persons with normal levels of cholesterol. J Clin Gastroenterol 25 (1997) 433-436
39. Smit J.W., Van Erpecum K.J., Gadella M.M., et al. Does the HMG-CoA reductase inhibitor pravastatin influence nucleation of cholesterol crystals in supersaturated model bile?. Eur J Gastroenterol Hepatol 8 (1996) 197-200
40. Saunders K.D., Cates J.A., Abedin M.Z., et al. Lovastatin and gallstone dissolution: a preliminary study. Surgery 113 (1993) 28-35
41. Chapman B.A., Burt M.J., Chisholm R.J., et al. Dissolution of gallstones with simvastatin, an HMG CoA reductase inhibitor. Dig Dis Sci 43 (1998) 349-353
42. Smit J.W., VanErpecum K.J., and VanBerge-Henegouwen G.P. Cholesterol synthesis inhibitors in cholesterol gallstone disease. Scand J Gastroenterol Suppl 218 (1996) 56-60
43. Sommeijer D.W., MacGillavry M.R., Meijers J.C., et al. Anti-inflammatory and anticoagulant effects of pravastatin in patients with type 2 diabetes. Diabetes Care 27 (2004) 468-473
44. Rosenson R.S., Tangney C.C., and Casey L.C. Inhibition of proinflammatory cytokine production by pravastatin. Lancet 353 (1999) 983-984
45. Rosenson R.S., and Tangney C.C. Anti-atherothrombotic properties of statins: implications for cardiovascular event reduction. JAMA 279 (1998) 1643-1650
46. Paolisso G., Barbagallo M., Petrella G., et al. Effects of simvastatin and atorvastatin administration on insulin resistance and respiratory quotient in aged dyslipidemic non-insulin dependent diabetic patients. Atherosclerosis 150 (2000) 121-127
47. Paolisso G., Sgambato S., De Riu S., et al. Simvastatin reduces plasma lipid levels and improves insulin action in elderly, non-insulin dependent diabetics. Eur J Clin Pharmacol 40 (1991) 27-31
48. Pontrelli L., Parris W., Adeli K., et al. Atorvastatin treatment beneficially alters the lipoprotein profile and increases low-density lipoprotein particle diameter in patients with combined dyslipidemia and impaired fasting glucose/type 2 diabetes. Metabolism 51 (2002) 334-342
49. Nielsen S., Schmitz O., Moller N., et al. Renal function and insulin sensitivity during simvastatin treatment in type 2 (non-insulin-dependent) diabetic patients with microalbuminuria. Diabetologia 36 (1993) 1079-1086
50. Gannage-Yared M.H., Azar R.R., Amm-Azar M., et al. Pravastatin does not affect insulin sensitivity and adipocytokines levels in healthy nondiabetic patients. Metabolism 54 (2005) 947-951
51. Misciagna G., Guerra V., Di Leo A., et al. Insulin and gall stones: a population case control study in southern Italy. Gut 47 (2000) 144-147
52. Tsai C.J., Leitzmann M.F., Willett W.C., et al. Glycemic load, glycemic index, and carbohydrate intake in relation to risk of cholecystectomy in women. Gastroenterology 129 (2005) 105-112
53. Tsai C.J., Leitzmann M.F., Willett W.C., et al. Macronutrients and insulin resistance in cholesterol gallstone disease. Am J Gastroenterol 103 (2008) 2932-2939
54. Rimm E.B., Stampfer M.J., Colditz G.A., et al. Validity of self-reported waist and hip circumferences in men and women. Epidemiology 1 (1990) 466-473
55. Feskanich D., Rimm E.B., Giovannucci E.L., et al. Reproducibility and validity of food intake measurements from a semiquantitative food frequency questionnaire. J Am Diet Assoc 93 (1993) 790-796